96 related articles for article (PubMed ID: 26343550)
1. Pharmacokinetics and pharmacodynamics of various glucagon dosages at different blood glucose levels.
Blauw H; Wendl I; DeVries JH; Heise T; Jax T;
Diabetes Obes Metab; 2016 Jan; 18(1):34-9. PubMed ID: 26343550
[TBL] [Abstract][Full Text] [Related]
2. Effects of subcutaneous, low-dose glucagon on insulin-induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes.
Ranjan A; Schmidt S; Madsbad S; Holst JJ; Nørgaard K
Diabetes Obes Metab; 2016 Apr; 18(4):410-8. PubMed ID: 26743775
[TBL] [Abstract][Full Text] [Related]
3. Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus.
Hövelmann U; Olsen MB; Mouritzen U; Lamers D; Kronshage B; Heise T
Diabetes Obes Metab; 2019 Mar; 21(3):601-610. PubMed ID: 30350477
[TBL] [Abstract][Full Text] [Related]
4. Comparative Pharmacokinetic/Pharmacodynamic Study of Liquid Stable Glucagon Versus Lyophilized Glucagon in Type 1 Diabetes Subjects.
Castle JR; Youssef JE; Branigan D; Newswanger B; Strange P; Cummins M; Shi L; Prestrelski S
J Diabetes Sci Technol; 2016 Sep; 10(5):1101-7. PubMed ID: 27325390
[TBL] [Abstract][Full Text] [Related]
5. Relationship between Optimum Mini-doses of Glucagon and Insulin Levels when Treating Mild Hypoglycaemia in Patients with Type 1 Diabetes - A Simulation Study.
Ranjan A; Wendt SL; Schmidt S; Madsbad S; Holst JJ; Madsen H; Knudsen CB; Jørgensen JB; Nørgaard K
Basic Clin Pharmacol Toxicol; 2018 Mar; 122(3):322-330. PubMed ID: 28922582
[TBL] [Abstract][Full Text] [Related]
6. Insulin degludec/insulin aspart produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes mellitus.
Heise T; Nosek L; Klein O; Coester H; Svendsen AL; Haahr H
Diabetes Obes Metab; 2015 Jul; 17(7):659-64. PubMed ID: 25772444
[TBL] [Abstract][Full Text] [Related]
7. Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656, and metformin.
Krentz AJ; Morrow L; Petersson M; Norjavaara E; Hompesch M
Diabetes Obes Metab; 2014 Nov; 16(11):1096-101. PubMed ID: 24909093
[TBL] [Abstract][Full Text] [Related]
8. Cross-Validation of a Glucose-Insulin-Glucagon Pharmacodynamics Model for Simulation Using Data From Patients With Type 1 Diabetes.
Wendt SL; Ranjan A; Møller JK; Schmidt S; Knudsen CB; Holst JJ; Madsbad S; Madsen H; Nørgaard K; Jørgensen JB
J Diabetes Sci Technol; 2017 Nov; 11(6):1101-1111. PubMed ID: 28654314
[TBL] [Abstract][Full Text] [Related]
9. The influence of multiple dosing and age on the pharmacokinetics and pharmacodynamics of glipizide in patients with type II diabetes mellitus.
Jaber LA; Ducharme MP; Edwards DJ; Slaughter RL; Grunberger G
Pharmacotherapy; 1996; 16(5):760-8. PubMed ID: 8888072
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of single-hormone and dual-hormone artificial pancreas during continuous and interval exercise in adult patients with type 1 diabetes: randomised controlled crossover trial.
Taleb N; Emami A; Suppere C; Messier V; Legault L; Ladouceur M; Chiasson JL; Haidar A; Rabasa-Lhoret R
Diabetologia; 2016 Dec; 59(12):2561-2571. PubMed ID: 27704167
[TBL] [Abstract][Full Text] [Related]
11. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
[TBL] [Abstract][Full Text] [Related]
12. Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study.
Chase HP; Lutz K; Pencek R; Zhang B; Porter L
J Pediatr; 2009 Sep; 155(3):369-73. PubMed ID: 19464026
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog.
Hövelmann U; Bysted BV; Mouritzen U; Macchi F; Lamers D; Kronshage B; Møller DV; Heise T
Diabetes Care; 2018 Mar; 41(3):531-537. PubMed ID: 29273578
[TBL] [Abstract][Full Text] [Related]
14. Insulin administered by needle-free jet injection corrects marked hyperglycaemia faster in overweight or obese patients with diabetes.
de Wit HM; Engwerda EE; Tack CJ; de Galan BE
Diabetes Obes Metab; 2015 Nov; 17(11):1093-9. PubMed ID: 26259978
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
Heise T; Hövelmann U; Nosek L; Hermanski L; Bøttcher SG; Haahr H
Expert Opin Drug Metab Toxicol; 2015; 11(8):1193-201. PubMed ID: 26086190
[TBL] [Abstract][Full Text] [Related]
16. Single- and Dual-Hormone Artificial Pancreas for Overnight Glucose Control in Type 1 Diabetes.
Haidar A; Rabasa-Lhoret R; Legault L; Lovblom LE; Rakheja R; Messier V; D'Aoust É; Falappa CM; Justice T; Orszag A; Tschirhart H; Dallaire M; Ladouceur M; Perkins BA
J Clin Endocrinol Metab; 2016 Jan; 101(1):214-23. PubMed ID: 26523526
[TBL] [Abstract][Full Text] [Related]
17. LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects.
Barrington P; Chien JY; Tibaldi F; Showalter HD; Schneck K; Ellis B
Diabetes Obes Metab; 2011 May; 13(5):434-8. PubMed ID: 21251179
[TBL] [Abstract][Full Text] [Related]
18. Quantification of the glycemic response to microdoses of subcutaneous glucagon at varying insulin levels.
El Youssef J; Castle JR; Bakhtiani PA; Haidar A; Branigan DL; Breen M; Ward WK
Diabetes Care; 2014 Nov; 37(11):3054-60. PubMed ID: 25139882
[TBL] [Abstract][Full Text] [Related]
19. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
[TBL] [Abstract][Full Text] [Related]
20. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
